Safety aspects of growth hormone replacement.
Waterhouse
Mona
M
Department of Endocrinology, St Bartholomew's Hospital (Queen Mary, University of London), London, UK.
Monson
John P
JP
D000328:Adult; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002352:Carrier Proteins / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced; D004487:Edema / Q000139:chemically induced; D018149:Glucose Intolerance / Q000209:etiology; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D019382:Human Growth Hormone / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D007018:Hypopituitarism / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000139:chemically induced; D010911:Pituitary Neoplasms / Q000139:chemically induced; D013963:Thyroid Hormones / Q000097:blood
D002352:Carrier Proteins; D013963:Thyroid Hormones; C027091:cortisol binding globulin; D019382:Human Growth Hormone; D006854:Hydrocortisone